Rarely are anti-trust measures needed to break up bad businesses. It's the good (well, good in the sense of effective, profitable, etc) businesses that tend to be the focus of those.
The same business can look good or bad depending on your perspective. Mylan is a great business from its shareholders perspective and a bad business from everyone else's, because it gouges consumers by charging $600 for some that costs ~$15.
Sanofi made AuviQ (EpiPen clone) but pulled out after regulators made Sanofi do a full-scale recall after several injector faults. Teva was set to provide its own generic version, but in the final stages of the review process, it was rejected by the FDA.
The solution was to create policy (and to punish Mylan for breaking policy that already existed). Conducting an antitrust break-up of Mylan would have only made things worse imo.